Evaluation of haematology POCT in oncology

Horiba UK Medical has announced the publication of two studies evaluating the use of its Yumizen H500 haematology analyser for point-of-care testing (POCT) to enhance the care of oncology patients. With near-patient, full blood count results, patients undergoing chemotherapy can receive treatment without delay and greatly reduce their hospital/clinic exposure times.

The evaluation studies were performed by the Cardiff and Vale Health Board (CAVHB), University Hospital of Wales and the Spire Bushey Laboratory in London. Both studies demonstrated that the compact, easy-to-use analyser delivered key parameters at the point of care that showed exceptional correlation with larger laboratory-based haematology analysers. Blood samples from oncology patients may be abnormal, having low counts and atypical blood cells, therefore it is essential that near-patient testing does not compromise the clinical integrity of results.

                Both studies found that in addition to speed and ease of use, the Yumizen H500’s functionality and audit systems fully adhere to ISO standards (15189:2012 and 22870:2016) with the same internal quality controls as larger analysers. This in turn ensured detailed, accurate results for timely and sound clinical decision-making.

www.horiba.com/en_en/products/by-segment/medical

 

Other news

Upcoming Events

Focus 2019

SEC Glasgow
1-3 May 2019

Respiratory Microbiology - A Day of Inspiration

Royal Air Force Museum, Hendon
16 May 2019

Clinical and Laboratory Haemostasis 2019

The Atrium Conference Centre, Sheffield Hallam University
5-6 June 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

IBMS Biomedical Science Congress

ICC, Birmingham
22-25 September 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Apr 2019

Reducing exposure to antimicrobial agents

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.